Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transcriptome analysis and pharmacogenomics].

T Tanaka1

  • 1Department of Molecular and Cellular Pharmacology, Mie University School of Medicine, Japan.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|November 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of actin-activated myosin Mg(2+)-ATPase in smooth muscle by ruthenium red.

FEBS letters·1992
Same author

Usefulness and limitation of measurement of insulin-like growth factor binding protein-3 (IGFBP-3) for diagnosis of growth hormone deficiency.

Endocrinologia japonica·1992
Same author

[The influence of paraquat on cell cycle--analysis of cell kinetics using DNA/BrdU staining].

Human cell·1992
Same author

Pulmonary surfactant apoprotein-A in neonates with different respiratory disorders.

Acta paediatrica Japonica : Overseas edition·1992
Same author

Effects of acute administration of nicotine on convulsive movements and blood levels of corticosterone in old rats.

Japanese journal of pharmacology·1992
Same author

[The prevalence of diabetes mellitus and impaired glucose tolerance studied by 75 gram oral glucose tolerance test in a rural island population].

[Nihon koshu eisei zasshi] Japanese journal of public health·1992
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

Pharmacogenomics uses genome sequencing and transcriptome analysis to identify drug responders. This strategy helps discover novel therapeutic targets by analyzing gene expression changes in disease models.

Area of Science:

  • Genomics and Molecular Biology
  • Pharmacology

Context:

  • Pharmacogenomics involves identifying genetic factors influencing drug response.
  • Genome sequencing, transcriptome, and proteome analysis are key tools.

Purpose:

  • To describe transcriptome analysis methods (differential display, cDNA microarray) for pharmacogenomics.
  • To identify therapeutic target genes using transcriptome analysis in animal models.

Summary:

  • Pharmacogenomics aims to personalize drug therapy by understanding individual genetic variations.
  • Transcriptome analysis, including differential display and cDNA microarrays, reveals gene expression patterns.
  • This study applied transcriptome analysis to oxidative stress and hypoxia models to find new drug targets.

Impact:

Related Experiment Videos

  • Enables the discovery of novel drug targets for various conditions.
  • Advances personalized medicine by linking genetic makeup to drug efficacy.
  • Provides a framework for identifying genetic markers of drug response and non-response.